LogicBio Therapeutics

$10.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.42 (-12.28%) As of 2:59 PM EDT today
-$1.42 (-12.28%) Today

Why Robinhood?

You can buy or sell LOGC and other stocks, options, ETFs, and crypto commission-free!

About LOGC

LogicBio Therapeutics, Inc. Common Stock, also called LogicBio Therapeutics, is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. Read More It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.

Employees
23
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
262.95M
Price-Earnings Ratio
Dividend Yield
Average Volume
27.66K
High Today
$11.45
Low Today
$9.88
Open Price
$11.45
Volume
76.84K
52 Week High
$20.07
52 Week Low
$6.34

Collections

LOGC Earnings

-$4.03
-$2.80
-$1.56
-$0.33
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Dec 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.